Antithrombin Dosing for Neuroprotection in Ischemic Stroke

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for ischemic stroke, such as recombinant tissue plasminogen activator (rtPA), have a narrow therapeutic time-window and fail to address the neurodegenerative processes that occur rapidly after stroke onset, leading to significant neural and neuronal damage.

Innovation Solution

Administration of antithrombin at specific doses to increase plasmatic antithrombin activity or concentration, mitigating stroke effects without increasing bleeding risk, and providing neuroprotection by reducing infarct volume and inflammation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If rtPA is used to dissolve blood clots and restore perfusion, then blood flow is re-established, but neurodegenerative processes and neural cell death continue to progress due to narrow therapeutic time-window

Engineering Contradiction:

Improveperfusion restorationVSAvoidneural protection

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies preliminary action by administering antithrombin before the onset of severe neurodegenerative processes. The treatment is initiated early in the stroke course to prevent harmful coagulation and inflammation cascades before they cause irreversible neural damage, rather than waiting for perfusion restoration to prevent damage.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses antithrombin as an intermediary substance that mediates between the ischemic stroke condition and neural tissue protection. Antithrombin acts as a multifunctional mediator that inhibits coagulation, reduces inflammation, and prevents neurodegeneration, thereby protecting neural tissue from the harmful effects of ischemia without requiring direct reperfusion.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If antithrombin is administered at high doses to increase plasmatic activity, then neuroprotection and reduction of infarct volume are achieved, but bleeding risk may increase

Engineering Contradiction:

Improveneural protectionVSAvoidbleeding risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by optimizing the dose and timing of antithrombin administration to achieve the minimum effective concentration for neuroprotection while avoiding excessive levels that would cause harmful bleeding effects. The treatment parameters are carefully adjusted to maintain plasmatic antithrombin activity within a therapeutic window that provides neural protection without excessive bleeding risk.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Antithrombin administration effectively reduces infarct volume and neuronal damage by enhancing anticoagulant and anti-inflammatory properties, improving neurological outcomes in stroke patients.

Implementation Method 1

Antithrombin administration effectively reduces infarct volume and neuronal damage by enhancing anticoagulant and anti-inflammatory properties

Methodology Applied

Scientific EffectAnticoagulation:

Implementation Method 2

Antithrombin administration effectively reduces infarct volume and neuronal damage by enhancing anticoagulant and anti-inflammatory properties

Methodology Applied

Scientific EffectAnti-inflammation:

Data Source

PatentUS20260022158A1Antithrombin in stroke

Publication Date: 2026.01.22 GRIFOLS WORLDWIDE OPERATIONS

AI summary

The present invention relates to the use of Antithrombin in the treatment of stroke.